Previous 10 | Next 10 |
home / stock / spgi / spgi articles
Goldman Sachs analyst George K. Tong expects companies in America's Business & Information Services sector to lean into technology and...
S&P Global (NYSE:SPGI) has outperformed the market over the past 10 years by 9.05% on an annualized basis producing an average annual return of...
S&P Global (NYSE:SPGI) has outperformed the market over the past 10 years by 9.24% on an annualized basis producing an average annual return of...
In the current session, the stock is trading at $405.54, after a 0.39% spike. Over the past month, S&P Global Inc. (NYSE:SPGI) stock increased ...
On CNBC’s "Halftime Report Final Trades," Josh Brown of Ritholtz Wealth Management named Apple, Inc. (NASDAQ: AAPL) as hi...
The CNN Money Fear and Greed index remained in the "Fear" zone on Thursday. U.S. stocks closed sharply higher on Thursday, amid a decline...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Thursday. The Dow traded up 1.51% to...
S&P Global (NYSE:SPGI) has outperformed the market over the past 10 years by 8.24% on an annualized basis producing an average annual return of...
S&P Global (NYSE:SPGI) has outperformed the market over the past 10 years by 8.73% on an annualized basis producing an average annual return of...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 10:15:02 ET BMO Capital analyst issues OUTPERFORM recommendation for SPGI on July 2, 2024 08:38AM ET. The previous analyst recommendation was Outperform. SPGI was trading at $446.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
S&P Global Schedules Second Quarter 2024 Earnings Announcement and Conference Call for Tuesday, July 30, 2024 S&P Global Schedules Second Quarter 2024 Earnings Announcement and Conference Call for Tuesday, July 30, 2024 PR Newswire NEW YORK , June 28, 202...
Protagonist Therapeutics Set to Join S&P SmallCap 600 Protagonist Therapeutics Set to Join S&P SmallCap 600 PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in ...